Therefore, this study aims to determine the effect of IFN-α and -β treatment on respiratory, cardiovascular, neurological, and psychiatric outcomes, PASC, and death in hospitalized COVID-19 patients. The gene discussed is IFNA1; the disease is COVID-19.